Hoping some better posters here may help me with a few questions below(i take a while to get their head around these scientific papers and what the breadcrumbs mean) for the Race opportunity;
With the upcoming cardio trials, does anyone have an idea of how many of the drugs listed in Doan's paper are likely to be tested for synergy/cardio protection? I assume this is based on the cancer type of patients that enroll and which drug works best for the cancer?
Is it likely we will get proof of synergy across several of the cancer drugs or will it be more concentrated on a few (ie the breast cancer drugs)?
I assume this is where the inferred/validated synergies will be validated?
Thanks JDP and others for the find and discussions. Takes a while to get your head around it but its starting to make sense. Wow what an opportunity in front of us!
DYOR and GLTAH.
Hoping some better posters here may help me with a few questions...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |